Eli Lilly/$LLY
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
- Ticker
- $LLY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 50,000
- Headquarters
- Indianapolis, United States
- Website
- www.lilly.com
Eli Lilly Metrics
BasicAdvanced
$1T
39.48
$29.79
0.51
$6.46
0.59%
Price and volume
Market cap
$1T
Beta
0.51
52-week high
$1,292.65
52-week low
$712.05
Average daily volume
2.6M
Dividend rate
$6.46
Financial strength
Current ratio
1.355
Quick ratio
0.679
Long term debt to equity
141.262
Total debt to equity
162.071
Dividend payout ratio (TTM)
21.66%
Interest coverage (TTM)
215.26%
Profitability
EBITDA (TTM)
41,707
Gross margin (TTM)
83.40%
Net profit margin (TTM)
33.53%
Operating margin (TTM)
49.72%
Effective tax rate (TTM)
20.49%
Revenue per employee (TTM)
$1,590,000
Management effectiveness
Return on assets (TTM)
20.36%
Return on equity (TTM)
102.29%
Valuation
Price to earnings (TTM)
39.481
Price to revenue (TTM)
13.197
Price to book
30.95
Price to tangible book (TTM)
151.52
Price to free cash flow (TTM)
76.308
Free cash flow yield (TTM)
1.31%
Free cash flow per share (TTM)
15.412
Dividend yield (TTM)
0.55%
Forward dividend yield
0.59%
Growth
Revenue change (TTM)
49.58%
Earnings per share change (TTM)
94.80%
3-year revenue growth (CAGR)
39.23%
10-year revenue growth (CAGR)
14.48%
3-year earnings per share growth (CAGR)
60.68%
10-year earnings per share growth (CAGR)
29.08%
3-year dividend per share growth (CAGR)
15.25%
10-year dividend per share growth (CAGR)
12.33%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.